Key Highlights
- Intraday market data put PepGen (NASDAQ:PEPG) at USD 4.16 on Thursday, November 19, 2026, a gain of 8.82%. Our searches turned up no company announcement dated that day.
- Expected gross proceeds total USD 125 million before fees, from a November 11, 2026 pricing of 25 million shares at USD 5.00.
- At the 10 mg/kg dose of PGN-EDODM1, mean splicing correction reached 46.5% in Phase 2 testing, while four of six participants exceeded 50% and five of six cleared 20%.
- Cash, equivalents and marketable securities totaled USD 104.8 million at September 30, 2026, against a third-quarter net loss of USD 19.4 million.
Shares Sit Below the USD 5 Offering Price
PepGen (NASDAQ:PEPG) traded at USD 4.16 during the Thursday, November 19, 2026 session after climbing 8.82% in intraday data. The price remains about 16.8% beneath the USD 5.00 offering level, a simple calculation from two published prices. Announced on November 11, the underwritten deal covered 25 million common shares, and underwriters hold a 30-day option on up to 3.75 million additional shares. Settlement was targeted for roughly November 13, with proceeds earmarked for clinical work, Working Capital and general corporate uses. Nothing dated November 17 to 19 was located, so the gain lacks a company-level trigger, and a sub-USD 5 stock can swing sharply on light volume.
Phase 2 Results Preceded the Financing
PepGen develops treatments at the clinical stage, and its Front-Running candidate, PGN-EDODM1, aims at myotonic dystrophy type 1. Data from the FREEDOM2-DM1 study's 10 mg/kg group came out on November 10, showing mean splicing correction of 46.5%. Participants also reported gains in hand opening speed, grip strength and walking pace, and no serious adverse events or dose-limiting toxicities emerged. A monitoring board endorsed the 12.5 mg/kg cohort next, now fully enrolled, and a readout is anticipated in the first half of 2027. Open-label extension data are slated for January 2027. Financing came a day later, a sequence often seen when small biotechs raise money after encouraging readouts.
Runway Math, the Partial Hold and Dilution
Before the offering, cash and securities stood at USD 104.8 million on September 30, a figure management said supports operations into 2028. Adding the USD 125 million gross brings the calculated total to roughly USD 229.8 million before fees and later spending. R&D spending came to USD 14.5 million in a quarter in which losses totaled USD 19.4 million, equal to USD 0.28 per share. The main hazard is a partial FDA clinical hold put in place in March 2026 following nonclinical mouse findings, and a potential end-of-Phase 2 regulatory meeting, aimed at the second half of 2027, depends on lifting it. New shares also dilute current holders, and quoted prices for low-priced stocks can reverse without warning.
Where Things Stand
Today's gain looks like a rebound inside a wider financing story, because no company notice dated November 19 was located. PepGen (NASDAQ:PEPG) is at USD 4.16 after rising 8.82%, which keeps it under the USD 5.00 that new buyers paid. Positives include favorable splicing results, USD 125 million in fresh capital and a cash runway guided into 2028. Offsetting points are the unresolved FDA partial hold, dilution and early-stage trial uncertainty. Watch the offering's closing, any change to the hold and the January 2027 extension update.




_11_19_2026_18_29_00_678569.jpg)

Please wait processing your request...